一个支持肿瘤学早期临床药物开发决策的建模与仿真框架。 - Suppr

Suppr

超能文献

A modeling and simulation framework to support early clinical drug development decisions in oncology.

作者信息

Bruno Rene, Lu Jian-Feng, Sun Yu-Nien, Claret Laurent

机构信息

Strategic Consulting Services, Pharsight-A Certara Company, Mountain View, California, USA.

出版信息

J Clin Pharmacol. 2011 Jan;51(1):6-8. doi: 10.1177/0091270010376970. Epub 2010 Jul 13.

DOI:10.1177/0091270010376970

PMID:20628172

Abstract

摘要

相似文献

A modeling and simulation framework to support early clinical drug development decisions in oncology.

J Clin Pharmacol. 2011 Jan;51(1):6-8. doi: 10.1177/0091270010376970. Epub 2010 Jul 13.

Evaluation of tumor size response metrics to predict survival in oncology clinical trials.

Clin Pharmacol Ther. 2014 Apr;95(4):386-93. doi: 10.1038/clpt.2014.4. Epub 2014 Jan 13.

A step toward optimization of cancer therapeutics. Physiologically based modeling of circadian control on cell proliferation.

IEEE Eng Med Biol Mag. 2008 Jan-Feb;27(1):20-4. doi: 10.1109/MEMB.2007.907363.

Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.

Clin Cancer Res. 2004 Jun 1;10(11):3885-96. doi: 10.1158/1078-0432.CCR-03-0785.

Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development.

Eur J Cancer. 2009 Sep;45 Suppl 1:436-8. doi: 10.1016/S0959-8049(09)70080-2.

Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling.

Int J Clin Pharmacol Ther. 1997 Oct;35(10):469-74.

Mathematical modeling of cancer progression and response to chemotherapy.

Expert Rev Anticancer Ther. 2006 Oct;6(10):1361-76. doi: 10.1586/14737140.6.10.1361.

The convergence of cancer prevention and therapy in early-phase clinical drug development.

Cancer Cell. 2004 Oct;6(4):321-6. doi: 10.1016/j.ccr.2004.09.021.

Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.

Clin Pharmacol Ther. 2015 Jan;97(1):37-54. doi: 10.1002/cpt.7. Epub 2014 Dec 9.

On the use of change in tumor size to predict survival in clinical oncology studies: toward a new paradigm to design and evaluate phase II studies.

Clin Pharmacol Ther. 2009 Aug;86(2):136-8. doi: 10.1038/clpt.2009.97.

引用本文的文献

Quantitative characterization of the effects of fulvestrant alone or in combination with taselisib (PI3Kinase inhibitor) on longitudinal tumor growth in patients with estrogen receptor-positive, HER2-negative, PIK3CA-mutant, advanced or metastatic breast cancer.

Cancer Chemother Pharmacol. 2024 Sep;94(3):421-436. doi: 10.1007/s00280-024-04690-4. Epub 2024 Jun 27.

Population pharmacokinetic-pharmacodynamic modeling of serum biomarkers as predictors of tumor dynamics following lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).

CPT Pharmacometrics Syst Pharmacol. 2024 Jun;13(6):954-969. doi: 10.1002/psp4.13130. Epub 2024 Mar 26.

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities.

CPT Pharmacometrics Syst Pharmacol. 2020 Aug;9(8):419-427. doi: 10.1002/psp4.12542. Epub 2020 Jul 22.

Predicting Overall Survival and Progression-Free Survival Using Tumor Dynamics in Advanced Breast Cancer Patients.

AAPS J. 2019 Jan 30;21(2):22. doi: 10.1208/s12248-018-0290-x.

Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer.

Clin Pharmacokinet. 2017 Jan;56(1):55-63. doi: 10.1007/s40262-016-0425-0.

Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling.

Clin Transl Sci. 2016 Feb;9(1):43-50. doi: 10.1111/cts.12384. Epub 2016 Jan 21.

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

CPT Pharmacometrics Syst Pharmacol. 2015 Jul;4(7):386-95. doi: 10.1002/psp4.49. Epub 2015 Jun 30.

Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression.

Br J Cancer. 2015 Feb 3;112(3):429-37. doi: 10.1038/bjc.2014.649. Epub 2015 Jan 13.

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST.

CPT Pharmacometrics Syst Pharmacol. 2013 Nov 20;2(11):e84. doi: 10.1038/psp.2013.61.

Modeling NSCLC progression: recent advances and opportunities available.

AAPS J. 2013 Apr;15(2):542-50. doi: 10.1208/s12248-013-9461-y. Epub 2013 Feb 13.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验